Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teniposide Combined With Temozolomide for Newly Diagnosed MGMT-Unmethylated Glioblastoma
NCT07894549Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2026
- Primary completion
- Mar 2030
01
Overview
Open-label, single-arm trial of teniposide in glioblastoma (GBM), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 24 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
teniposide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07894549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07894549.